2.26
price up icon25.56%   0.46
after-market Handel nachbörslich: 2.17 -0.09 -3.98%
loading
Schlusskurs vom Vortag:
$1.80
Offen:
$1.64
24-Stunden-Volumen:
871.77K
Relative Volume:
2.89
Marktkapitalisierung:
$61.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.81M
KGV:
-1.0482
EPS:
-2.156
Netto-Cashflow:
$-42.93M
1W Leistung:
+4.63%
1M Leistung:
-36.34%
6M Leistung:
-79.53%
1J Leistung:
-84.44%
1-Tages-Spanne:
Value
$1.64
$2.29
1-Wochen-Bereich:
Value
$1.60
$2.29
52-Wochen-Spanne:
Value
$1.60
$17.55

Alto Neuroscience Inc Stock (ANRO) Company Profile

Name
Firmenname
Alto Neuroscience Inc
Name
Telefon
773-255-5012
Name
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Name
Mitarbeiter
76
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ANRO's Discussions on Twitter

Vergleichen Sie ANRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ANRO
Alto Neuroscience Inc
2.26 61.18M 0 -49.81M -42.93M -2.156
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-23 Herabstufung Rodman & Renshaw Buy → Neutral
2024-10-23 Herabstufung Wedbush Outperform → Neutral
2024-09-03 Eingeleitet Wedbush Outperform
2024-02-27 Eingeleitet Jefferies Buy
2024-02-27 Eingeleitet Robert W. Baird Outperform
2024-02-27 Eingeleitet Stifel Buy
2024-02-27 Eingeleitet TD Cowen Outperform
2024-02-27 Eingeleitet William Blair Outperform
Alle ansehen

Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten

pulisher
11:49 AM

Alto Neuroscience initiated with a Buy at H.C. Wainwright - TipRanks

11:49 AM
pulisher
Apr 01, 2025

Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World

Apr 01, 2025
pulisher
Mar 30, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 24, 2025

What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Alto Neuroscience says its funded through 2028 - Green Market Report

Mar 21, 2025
pulisher
Mar 20, 2025

ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Alto Neuroscience Inc. (ANRO) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Alto Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire

Mar 20, 2025
pulisher
Mar 13, 2025

Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

ANRO stock touches 52-week low at $3.23 amid market challenges - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR

Mar 07, 2025
pulisher
Mar 06, 2025

Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World

Mar 06, 2025
pulisher
Mar 04, 2025

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable

Mar 04, 2025
pulisher
Mar 04, 2025

1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart

Mar 04, 2025
pulisher
Mar 02, 2025

Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance

Mar 02, 2025
pulisher
Feb 27, 2025

Alto Neuroscience advances trial for depression treatment - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

ANRO stock touches 52-week low at $2.97 amid market challenges - Investing.com Canada

Feb 26, 2025
pulisher
Feb 25, 2025

Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire

Feb 25, 2025
pulisher
Feb 19, 2025

Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire

Feb 19, 2025
pulisher
Feb 14, 2025

Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 13, 2025
pulisher
Feb 13, 2025

Stifel maintains Buy on Alto Neuroscience stock, $10 target - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

Alto Neuroscience advances trial for depression treatment By Investing.com - Investing.com Australia

Feb 12, 2025
pulisher
Feb 12, 2025

Stifel maintains Buy on Alto Neuroscience stock, $10 target By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 12, 2025

Alto Neuroscience : Corporate Presentation -February 12, 2025 at 08:29 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Alto Neuroscience announces interim analysis from ALTO-300 trial - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - The Bakersfield Californian

Feb 12, 2025
pulisher
Feb 05, 2025

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Louisiana First News

Feb 05, 2025
pulisher
Feb 04, 2025

Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR

Feb 04, 2025
pulisher
Feb 04, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Alto Neuroscience announces $75 million ATM offering - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK

Feb 03, 2025
pulisher
Feb 01, 2025

Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Feb 01, 2025

Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Kapitalisierung:     |  Volumen (24h):